Anna Windle
Anna Windle is the Director of Clinical Development, Medical and Regulatory Affairs at Novo Nordisk in the USA. She has been instrumental in the company's efforts to innovate in obesity treatment, particularly in the development of an oral version of the weight-loss medication Wegovy. Windle's insights emphasize the growing demand for individualized treatment plans that accommodate patient preferences, marking a significant shift in the approach to obesity management.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Anna Windle, PhD, senior vice president of clinical development, medical and regulatory affairs at Novo Nordisk, discusses the potential new treatment option for patients.
8
Denmark:
Anna Windle is the director of clinical development, medical and regulatory affairs at Novo Nordisk in the USA.
8